How Does Wegovy Actually Work? The Mechanism, Explained

How does Wegovy actually work?

Semaglutide, the drug in Wegovy, is a GLP-1 receptor agonist. It is a lab-made version of glucagon-like peptide-1, a hormone your gut releases after you eat. Natural GLP-1 fades within minutes. Semaglutide is built to last about a week per shot. That turns a brief after-meal signal into one your body feels all week.

That steady signal does three things, and none of them burns fat directly:

• Slows stomach emptying: food stays in your stomach longer, so you feel full longer after a meal.
• Quiets hunger in the brain: it acts on appetite centers in the hypothalamus. Many people also notice less background "food noise."
• Steadies blood sugar: it triggers insulin only when blood sugar is already high and lowers glucagon, a hormone that raises it. That's why it rarely causes sugar crashes on its own.

So weight loss on Wegovy comes from eating less over time, not from a faster metabolism. That explains two things. Results level off once your eating settles. And appetite tends to come back if you stop, because the signal was doing the work.

What is Wegovy approved to treat?

Wegovy now has three FDA-approved uses. The first, from 2021, is chronic weight management. It covers adults with obesity, or with overweight plus a weight-related condition such as high blood pressure. It's meant to go with a lower-calorie diet and more activity. The second, from 2024, lowers the risk of heart attack, stroke and heart-related death in adults with heart disease and excess weight. It followed the SELECT trial.

The third, from 2025, is an accelerated approval for MASH with moderate to advanced liver scarring, before cirrhosis. MASH is a serious form of fatty liver disease. The FDA also approved the Wegovy pill, a daily tablet, in December 2025. Wegovy HD, a stronger 7.2 mg weekly shot, followed in March 2026.

Ozempic is the same drug, but all its approved uses are for people with type 2 diabetes. That detail trips up almost everyone who compares the two.

Why would a 45-year-old without diabetes be prescribed Wegovy?

Because Wegovy's approval was never about blood sugar. You qualify with a BMI of 30 or higher, or 27 or higher with a weight-related condition. Those include high blood pressure, high cholesterol or sleep apnea. Diabetes isn't on the list. A woman in perimenopause who meets that bar is getting Wegovy for exactly its approved use. That's unlike Ozempic for weight loss, which is off-label.

There's a reason this comes up more in your 40s and 50s. Falling, swinging estrogen tends to move fat toward the belly and weakens insulin response. Those changes can push a woman over the BMI or health-condition bar for the first time in midlife. The drug works the same at any stage, but the body it acts on often changes. Our GLP-1 and menopause guide covers how that overlap plays out.

Is Wegovy just Ozempic at a higher dose?

Chemically, yes. Both contain semaglutide. What separates them is the top dose and the approval. The Ozempic pen tops out at 2 mg a week and is approved for type 2 diabetes. The Wegovy pen goes to 2.4 mg, or 7.2 mg with Wegovy HD, and carries the weight, heart and liver approvals above.

Using Ozempic for weight loss is common and often works. But it's off-label, leaning on Wegovy's own trials rather than its own. How Ozempic works, and on what timeline covers that picture. Our look at semaglutide compares every form side by side: Ozempic, the Ozempic pill formerly sold as Rybelsus, Wegovy and compounded versions.

How is Wegovy different from Zepbound?

Here the drug itself changes. Zepbound's active ingredient is tirzepatide, a different molecule from semaglutide. Wegovy acts on one receptor, GLP-1. Tirzepatide acts on two at once: GLP-1 and GIP, a second gut hormone involved in insulin release and fat storage. Combining the two signals appears to give a stronger appetite and metabolic effect.

The trial data shows it. In SURMOUNT-5, the first head-to-head trial of the two, people lost about 20% of their weight on tirzepatide at 72 weeks, against about 14% on semaglutide. That's a real gap, but not the whole decision. Cost, side effects and your own response matter too. Wegovy vs. Zepbound weighs results against price.

How fast do you actually feel any of this?

The first doses are kept low on purpose. Their job is to let your gut adjust, not to treat yet. Appetite is usually the first thing to shift, often within the first couple of weeks as the dose climbs. The step-by-step schedule is in the Wegovy dosage chart. What changes about eating day to day, including alcohol, is in the Wegovy diet guide.

Does anything change once perimenopause is part of the picture?

The receptor biology doesn't change. GLP-1 receptors respond the same way at any stage of life. What changes is the starting point. Fat may already have shifted toward the belly, and muscle mass tends to decline in midlife. Neither stops semaglutide from working. They just mean the baseline looks different.

One detail matters going in. Eating less affects what you lose in general, not only fat. In a body-scan substudy of the STEP 1 trial, about 4 of every 10 pounds lost on semaglutide were lean mass, which includes muscle. That matters more after 40, when muscle is already harder to keep. It's a reason to pair the medicine with protein and strength training, not a reason to avoid it.

GLP-1 and muscle loss in perimenopause covers what protects muscle during treatment. For common side effects and which ones are serious, see Wegovy side effects.